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Despite the crucial role of RAF kinases in cell signaling and
disease, we still lack a complete understanding of their regulation.
Heterodimerization of RAF kinases as well as dephosphorylation
of a conserved “S259” inhibitory site are important steps for RAF ac-
tivation but the precise mechanisms and dynamics remain unclear. A
ternary complex comprised of SHOC2, MRAS, and PP1 (SHOC2 com-
plex) functions as a RAF S259 holophosphatase and gain-of-function
mutations in SHOC2, MRAS, and PP1 that promote complex forma-
tion are found in Noonan syndrome. Here we show that SHOC2
complex-mediated S259 RAF dephosphorylation is critically required
for growth factor-induced RAF heterodimerization as well as for
MEK dissociation from BRAF. We also uncover SHOC2-independent
mechanisms of RAF and ERK pathway activation that rely on N-
region phosphorylation of CRAF. In DLD-1 cells stimulated with
EGF, SHOC2 function is essential for a rapid transient phase of
ERK activation, but is not required for a slow, sustained phase that
is instead driven by palmitoylated H/N-RAS proteins and CRAF.
Whereas redundant SHOC2-dependent and -independent mecha-
nisms of RAF and ERK activation make SHOC2 dispensable for pro-
liferation in 2D, KRAS mutant cells preferentially rely on SHOC2 for
ERK signaling under anchorage-independent conditions. Our study
highlights a context-dependent contribution of SHOC2 to ERK path-
way dynamics that is preferentially engaged by KRAS oncogenic
signaling and provides a biochemical framework for selective ERK
pathway inhibition by targeting the SHOC2 holophosphatase.
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Signaling by the RAF-MEK-ERK (ERK-MAPK) pathway isused by many extracellular signals to mediate a vast array of
biological responses in a cell-type–dependent manner. The mech-
anisms regulating signal specificity remain poorly understood but
are known to include modulators, scaffolds, feedbacks, and cross-
talk with other signaling pathways that jointly control spatial and
temporal dynamics of ERK activation. This in turn regulates
phosphorylation of different ERK substrates in a cell-type–, com-
partment-, and context-dependent manner (1, 2).
Aberrant activation of the ERK pathway is one of the most
common defects in human cancer, with oncogenic mutations in RAS
and RAF genes found in ∼30% and ∼8% of cancers, respectively.
Up-regulated ERK signaling is also responsible in a family of de-
velopmental disorders, referred to as RASopathies (3–5).
ERK pathway inhibitors have shown little clinical benefit
against RAS mutant tumors because of resistance and toxicity
(5). Strikingly, in both RAS and BRAF mutant cells, most re-
sistance mechanisms lead to ERK pathway reactivation, high-
lighting a strong “oncogene addiction” of these cancers to ERK
signaling. However, the potent pathway suppression required for
antitumor activity is limited by the inhibitor doses that can be
administered safely because of toxicity (6, 7). ERK activity is
essential for normal tissue homeostasis and systemic ablation of
MEK1/2 or ERK1/2 genes in adult mice leads to death of the
animals from multiple organ failure within 2–3 wk, even under
conditions of partial inactivation (8), highlighting the difficulties of
inhibiting the ERK pathway with a therapeutic index. To effectively
harness the addiction of RAS mutant cancers to ERK signaling
into viable therapies, new strategies to inhibit the pathway with
improved therapeutic margins are needed, for example by inhib-
iting ERK signaling in a context- or compartment-dependent
manner (9, 10).
MEK and ERK kinases are fully activated by phosphorylation
in two sites within its kinase domain by RAF and MEK, re-
spectively. On the other hand, RAF activation is a complex mul-
tistep process that remains incompletely understood (11). A
consensus model stipulates that under resting conditions, the three
RAF kinases (ARAF, BRAF, and CRAF/RAF1) are kept in the
cytosol in an inactive state by an intramolecular interaction me-
diated by 14-3-3 dimers binding in a phosphorylation-dependent
manner to conserved sites at the N terminus (S214 ARAF, S365
BRAF, S259 CRAF, hereby referred to as the “S259” site) and C-
terminal end (S729 in BRAF, S621 in CRAF) (11–13). Upon
activation, RAS-GTP binds with high affinity to the RAS binding
domain (RBD) of RAF and recruits RAF to the membrane where
the cysteine-rich domain (CRD) also plays a role in membrane
anchoring. Dephosphorylation of the S259 site is known to provide
an additional activating input that releases the 14-3-3 from this site
and allows RAF to adopt an open conformation where RAF di-
merizes with other RAFs, as well as KSR proteins. Definitive
confirmation of this model, however, awaits the crystal structure of
full-length RAF with or without bound 14-3-3. Nevertheless,
the importance of the S259 dephosphorylation regulatory step
is highlighted by RAF1 gain-of-function mutations in Noonan
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syndrome that cluster around S259 to disrupt the interaction with
14-3-3 (14–17). Furthermore, although RAF1 mutations are rare in
cancer, they cluster on residues S257 and S259 (cosmic database).
The precise dynamics and mechanism of S259 dephosphory-
lation remain unclear (11). We have previously shown that
MRAS, a closely related member of the RAS family, upon ac-
tivation forms a complex with the leucine-rich repeat protein
SHOC2 and protein phosphatase 1 (PP1) that functions as a
highly specific S259 RAF holophosphatase (18, 19). The im-
portance of the SHOC2-MRAS-PP1 complex (SHOC2 complex)
in RAF-ERK regulation is validated by gain-of-function muta-
tions in Noonan syndrome in all three components—SHOC2,
MRAS, and PP1—which promote phosphatase complex forma-
tion (20–23). On the other hand, the phosphatase PP2A has also
been variously implicated in mediating S259 dephosphorylation
(24–27), although this was primarily based on the use of okadaic
acid and the misconception that it behaves as a specific PP2A
inhibitor (28) (in addition to not discriminating between direct or
indirect effects). Furthermore, in contrast to its role as a regu-
latory subunit within a phosphatase complex, other studies have
suggested that SHOC2 can function as a scaffold that promotes
the RAS–RAF interaction (29–33).
RAF proteins also undergo multiple activating phosphoryla-
tion events. Among them, phosphorylation within the negative-
charge regulatory region (N-region) plays a key divergent role
among RAF paralogues (11). In CRAF, S338 and Y341 phos-
phorylation within the S338SYY341 motif by PAK and SRC family
kinases (SFK) plays a crucial role in regulated activation (34). In
contrast, the homologous S446SDD motif in BRAF constitutively
provides the negative charges required for activity by virtue of
acidic D amino acids and constitutive S446 phosphorylation (11,
34, 35). This difference in N-region regulation is believed to
account for BRAF having higher basal activity, being the most
frequent RAF target for mutational activation in cancer and for
BRAF being the initial activator in asymmetric RAF hetero-
dimers (11, 36).
In this study, we have used RNAi and CRISPR to ablate
SHOC2 and RAF function, as well as phosphoproteomics to
comprehensively characterize the role of the SHOC2 phospha-
tase complex in RAF and ERK pathway regulation. We have
uncovered a selective role for SHOC2 in ERK pathway dynamics,
and show that although SHOC2 phosphatase-mediated de-
phosphorylation of the S259 site is critically required for growth
factor-induced RAF heterodimerization, there also exist SHOC2-
independent mechanisms of ERK activation, which are dependent
on N-region phosphorylation of CRAF. Importantly, KRAS on-
cogenic signaling differentially relies on SHOC2-dependent mech-
anisms, which provides both a therapeutic opportunity and a
molecular framework for selective inhibition of ERK signaling in a
compartment and context-dependent manner.
Results
MRAS and SHOC2 Expression Promotes S365 BRAF/S259 CRAF
Dephosphorylation, BRAF-MEK Dissociation, and BRAF-CRAF Dimerization.
To study the role of the SHOC2 complex in the regulation of RAF
kinases, we generated an inducible T-REx-293 cell line (T-17 cells)
where addition of the tetracycline analog Doxycycline (Dox) leads
to expression of active MRAS-Q71L and SHOC2. In these cells,
Dox-induced MRAS/SHOC2 expression led to potent S365 de-
phosphorylation of ectopic TAP6-BRAF that is inhibited in a
dose-dependent manner by the serine/threonine phosphatase in-
hibitor calyculin A (Fig. 1A). To assess possible RAF regions in-
volved in S259 dephosphorylation, transiently transfected BRAF
and CRAF mutants were tested for dephosphorylation upon ex-
pression of MRAS/SHOC2. Among the mutants tested, only the
RBD mutants R188L BRAF and R89L CRAF were defective for
MRAS/SHOC2-induced S365/S259 dephosphorylation (Fig. 1 B
and C). Interestingly, when the CRAF R89L RBD mutant was
constitutively localized to the membrane by fusion with a RAS
membrane-targeting region (CRAF-CAAX R89L), S259 dephos-
phorylation was efficiently induced by MRAS/SHOC2 expression
(Fig. 1C). Taken together, these data suggest that membrane re-
cruitment through interaction with the RBD is required for effi-
cient S259 RAF dephosphorylation.
MRAS/SHOC2 expression levels in T-17 cells did not prove to
be tuneable because at the lowest Dox concentration that in-
duced expression, there was a maximum effect on MRAS/
SHOC2 protein levels and concomitant S365 dephosphorylation
(Fig. 1 D and E). When ectopic T6-BRAF in these cells was
purified with streptactin beads, MRAS/SHOC2 expression led to
a decrease in the amount of MEK bound to T6-BRAF and a
concomitant interaction of T6-BRAF with CRAF (Fig. 1 D and
E). To further study the specificity of the role for MRAS/
SHOC2 on RAF–MEK interactions, GST-pulldown assays were
performed after cotransfection of myc-MEK1 with GST-tagged
CRAF, BRAF, and KSR1 in HEK293T cells. Under basal con-
ditions, MEK1 bound most strongly to KSR1 and only weakly to
CRAF (KSR1 > BRAF >> CRAF), and Dox-induced MRAS/
SHOC2 expression led to strong dissociation of MEK from
BRAF and CRAF but not from KSR1 (Fig. 1F). Taken together,
the above data suggest that MRAS/SHOC2-induced S365 BRAF
dephosphorylation promotes MEK dissociation from BRAF and
BRAF heterodimerization with CRAF.
SHOC2 Is Required for EGF-Induced S365/S259 Dephosphorylation,
RAF Dimerization, BRAF-MEK Dissociation, and Efficient ERK Pathway
Activation. To assess the role of endogenous SHOC2 within the
context of growth factor signaling, T-REx-293 cells where SHOC2
expression was stably inhibited by shRNA expression were used to
analyze lysates and immunoprecipitates (IPs) of endogenous RAS
and RAF proteins in a time course of EGF treatment. EGF-
stimulated S365 BRAF dephosphorylation, MEK, ERK, and RSK
phosphorylation, but not AKT and EGFR Y1068 phosphoryla-
tion, were severely impaired in SHOC2 knockdown (KD) cells,
consistent with a selective role of SHOC2 in RAF-ERK pathway
activation (Fig. 2A).
When immunoprecipitating RAF, MEK can be readily de-
tected in complex with BRAF but not CRAF under basal con-
ditions (37), and higher levels of P-S365 BRAF in SHOC2 KD
cells correlate with higher levels of MEK and 14-3-3 bound to
BRAF (Fig. 2 A and B). EGF stimulated MEK and 14-3-3 dis-
sociation from BRAF and BRAF binding to CRAF, and this
response is strongly inhibited in SHOC2 KD cells (Fig. 2B). EGF-
induced BRAF interaction with KSR is also impaired in the
absence of SHOC2 (Fig. 2C and SI Appendix, Fig. S1A). In clear
contrast, RAF interaction with RAS, as measured on RAS IPs,
was not impaired but enhanced in SHOC2 KD cells (Fig. 2B),
likely as a result of loss of inhibitory feedbacks (see Discussion).
To extend these observations to other cell lines, a CRISPR/
CAS9 strategy was used to completely ablate SHOC2 function in
DLD-1 KRASG13D colon carcinoma cells. EGF-induced dephos-
phorylation of P-S365/S259 B/CRAF is impaired in SHOC2
knockout (KO) cells (Fig. 2D). Similarly, EGF-stimulated phos-
phorylation of MEK, ERK, and RSK, but not AKT, is strongly
inhibited in SHOC2 KO cells and this response is rescued by
reexpression of SHOC2WT but not SHOC2 mutants defective for
interaction with MRAS and PP1, such as D175N or RVxF-SILK
(18, 19, 23) (Fig. 2D). SHOC2 E457K disrupts MRAS/
PP1 interaction less efficiently (19, 23) and only partially rescues
ERK pathway activation by EGF. Therefore, ERK pathway reg-
ulation by SHOC2 correlates well with its ability to form a ternary
complex with MRAS and PP1.
To analyze RAF interactions in DLD-1 KO cells, endogenous
RAF IPs were performed on a time course of EGF stimulation as
before. In parental DLD-1 cells, EGF stimulates transient S365
BRAF dephosphorylation with dynamics that mirror MEK and 14-
3-3 dissociation from BRAF and BRAF dimerization with ARAF
and CRAF (Fig. 2 E and F). As seen in T-REx-293 KD cells,
SHOC2 KO DLD-1 have higher basal levels of MEK and 14-3-
3–bound BRAF complexes. Moreover, EGF-simulated MEK and
14-3-3 dissociation from BRAF and BRAF heterodimerization
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with CRAF and ARAF are strongly impaired in SHOC2 KO cells
(Fig. 2E).
To further validate that the effect of SHOC2 ablation on ERK
pathway activation was dependent on its function within an S259
RAF holophosphatase, T6-BRAFWT and S365A mutant (which
cannot be phosphorylated and therefore should be insensitive to
the phosphatase function of the SHOC2 complex) were stably
expressed in parental and SHOC2 KO DLD-1 cells. Expression
of BRAF S365A (unlike BRAF WT) leads to higher basal P-
MEK and P-ERK levels in both parental and SHOC2 KO cells,
consistent with ERK pathway activation by these RAF mutants
being insensitive to regulation by SHOC2 (Fig. 2G). When ec-
topic T6-BRAF was purified from these cells with streptactin
beads, T6-BRAF WT displayed higher basal MEK binding in
SHOC2 KO cells, whereas no MEK can be detected in complex
with T6-BRAF S365A, consistent with a role for S365 de-
phosphorylation in the regulation of the BRAF-MEK interaction
(Fig. 2G).
Taken together, the above results strongly suggest that
SHOC2 complex-mediated S259 RAF dephosphorylation is re-
quired for 14-3-3 dissociation from RAFs, MEK dissociation
from BRAF, and BRAF heterodimerization with ARAF, CRAF,
and KSR, but not for RAF binding to RAS (SI Appendix,
Fig. S2).
SHOC2 Is Selectively Required for Early but Not Late ERK Pathway
Activation by EGF in DLD-1 cells. When ERK pathway dynamics
were studied in an EGF time course in DLD-1 isogenic cells,
MEK, ERK, and RSK phosphorylation was strongly impaired at
early time points (2.5–5 min) in SHOC2 KO cells compared with
parental cells, whereas little differences were seen between them
by 20 min of EGF treatment (Fig. 3 A and B). Similar effects were
seen on downstream ERK targets sites, such as BRAF T753,
CRAF S289/296/301, EGFR T699, and IRS S363/639 feedback
sites, as well as RSK targets, such as YB1 S102 (Fig. 3A). No effect
was seen in ERK-independent sites on AF6 or RPS6, whereas
AKT S473 phosphorylation is enhanced in the absence of SHOC2,
consistent with a negative feedback crosstalk upon ERK pathway
inhibition (38, 39). This response is reproducibly seen in multiple
DLD-1 SHOC2 KO clones tested, ruling out clonal variation
(SI Appendix, Fig. S3 A and B) and is completely rescued by
reexpression in KO cells of SHOC2 WT but not the MRAS/
PP1 interaction-defective SHOC2 D175N (SI Appendix, Fig. S3
C and D).
When other agonists, such as lysophosphatidic acid and FBS
were used to stimulate DLD-1 cells, ERK activation was sim-
ilarly impaired preferentially at early time points in the ab-
sence of SHOC2. On the other hand, ERK activation by TNF-
α (which is RAS-RAF independent) was completely unaffected
(SI Appendix, Fig. S3 E and F). Taken together, these results are
consistent with an agonist-dependent biphasic ERK activation re-
sponse in which a rapid, transient phase requires the SHOC2
complex, whereas a slow, sustained phase is independent of
SHOC2 (Fig. 3C).
Phosphoproteomic Analysis of SHOC2’s Contribution to EGF-Regulated
Dynamics. To further study the contribution of SHOC2 to ERK
pathway dynamics in an unbiased manner, a label-free phospho-
proteomic approach was used to compare global EGF-regulated
phosphorylation in parental or SHOC2 KODLD-1 cells. TheMEK
inhibitor Trametinib was also used in parental cells to compare
global pharmacological pathway inhibition to genetic SHOC2 in-
hibition (Fig. 4A).
In total, 7,053 phosphosites were quantified, corresponding to
3,091 inferred proteins. In parental cells that were stimulated
with EGF, 89 and 78 phosphosites were found to be significantly
regulated at 5 and 20 min, respectively (cutoffs: fold-change ± 2,
adjusted P < 0.05) (Fig. 4B and Dataset S1). Functional and
phosphorylation motif analysis of the inferred proteins in pa-
rental cells are shown in SI Appendix, Fig. S4. Pretreatment with
Trametinib dramatically reduced EGF-regulated phosphoryla-
tion events with only 5 and 10 phosphosites significantly regu-
lated at 5 and 20 min, respectively (94% and 87% inhibition
compared with untreated cells) (Fig. 4B). This highlights the
crucial role of the ERK pathway in early signaling by EGF either
directly or indirectly by providing priming phoshophorylation for
other EGF-regulated kinases (40).
In SHOC2 KO cells, inhibition of EGF-regulated phosphor-
ylation was significantly more pronounced at 5 min than 20 min
of EGF treatment (90% vs. 38.5% inhibition, respectively) (Fig.
4B). When the phosphoproteomes of parental and SHOC2 KO
cells were compared at either 5 or 20 min of EGF treatment,
only 1 phosphosite was significantly changed at 20 min, whereas
26 phosphosites were differentially regulated by EGF in parental
but not SHOC2 KO cells at 5 min (21 down-regulated in SHOC2
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Fig. 1. MRAS and SHOC2 expression promotes S365
BRAF/S259 CRAF dephosphorylation, BRAF-MEK dissocia-
tion, and BRAF-CRAF dimerization. (A) Calyculin A inhibits
BRAF S365 dephosphorylation and ERK activation by
MRAS-SHOC2 expression. Expression of MRAS L71 and
SHOC2 was induced in T-17 cells stably expressing T6-BRAF
by 1 μg/mL Dox treatment for 24 h. Cells were incubated
with a Calyculin A dose–response for 20 min and lysates
immunoprobed, as indicated. (B) Intact RBD is required for
efficient S365 BRAF dephosphorylation by MRAS-SHOC2
expression: T6-BRAF WT and mutants were transiently
transfected into T-17 cells and MRAS-SHOC2 expression in-
duced for 24 h. (C) Impaired MRAS-SHOC2 induced S259
dephosphorylation by R89L RBD CRAF mutation is rescued
by constitutive membrane localization. As in B but with T6-
CRAF mutants. (D) MRAS-SHOC2 expression stimulates
BRAF S365 dephosphorylation, MEK dissociation, and CRAF
binding to BRAF. T-17 T6-BRAF cells as in A were treated
with different Dox concentrations for 24 h. StrepTactin pull-
downs of T6-BRAF and lysates were immunoprobed and
visualized using a Li-COR Odyssey scanner. (E) Li-Cor quan-
tification of D. (F) MRAS-SHOC2 expression stimulates
MEK1 dissociation from BRAF and CRAF but not KSR1.
GST-fusion genes were cotransfected into HEK293T cells,
together with Myc-MEK1 and either empty vector or
MRAS-L71 and SHOC2. GST-S6Kwas used as a control. GST
pull-downs and lysates were probed as indicated.
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KO cells, 5 up-regulated) (Fig. 4C). Selected examples of these
phosphosites are shown in SI Appendix, Fig. S4C. In conclusion,
using phosphoproteomic profiling, we independently determined
a selective contribution of SHOC2 to ERK pathway dynamics
with a preferential role of SHOC2 at early (5 min) vs. late
(20 min) times of EGF treatment.
SHOC2-Independent Late ERK Activation Requires CRAF. To address
the contribution of RAF isoforms to early vs. late SHOC2-
dependent and -independent mechanisms of ERK activation,
CRISPR was used to knock out the three RAF paralogues in
DLD-1 cells. In contrast to SHOC2 deletion, ablation of one or
any two combinations of RAF isoforms had no significant effect
on EGF-stimulated ERK activation (Fig. 5 A and B and SI Ap-
pendix, Fig. S5 A–D). However, KD of the remaining CRAF in
dual A/B RAF KO cells potently inhibits EGF-stimulated ERK
activation (Fig. 5B) and proliferation in colony formation assays
(SI Appendix, Fig. S5E). Thus, as observed in other systems (41,
42), there is redundancy among RAF isoforms but RAF function
is essential for ERK activation and proliferation of DLD-1 cells.
When siRNAs where used to acutely inhibit expression of
individual RAF isoforms, transient KD of individual RAF pro-
teins in parental DLD-1 cells had no effect on EGF-stimulated
ERK phosphorylation, consistent with the complementation
observed in RAF KO cells. In clear contrast, however, CRAF
KD (but not ARAF or BRAF) strongly inhibited MEK and ERK
phosphorylation in SHOC2 KO cells (Fig. 5 C and D). Similar
results were observed in HEK293T cells, although CRAF KD
has a modest inhibitory effect in control cells as well (SI Appendix,
Fig. S5F). Strong ERK pathway inhibition upon combined
SHOC2 and CRAF inhibition correlates with a strong inhibition
of proliferation in DLD-1 cells (Fig. 5E). Taken together, these
data suggest that, whereas there is redundancy among RAF iso-
forms in an early phase of SHOC2-dependent ERK pathway ac-
tivation, CRAF is the primary RAF kinase driving sustained ERK
activation by EGF in the absence of SHOC2.
SHOC2-Independent ERK Activation Requires Palmitoylated HRAS/
NRAS and CRAF N-Region Phosphorylation. Previous studies have
shown a biphasic HRAS activation response to EGF with a rapid
transient phase occurring at the plasma membrane, followed—
with a 10- to 20-min delay—by a sustained phase at the Golgi (43,
44), that is strikingly reminiscent of the ERK response observed in
this study. Futhermore, HRAS can differentially activate CRAF in
some contexts (45, 46). We thus used siRNAs to investigate the
contribution of RAS isoforms to ERK activation by EGF.
KD of any RAS protein had no effect on ERK activity in
parental DLD-1 cells, consistent with redundancy as observed
for RAF isoforms. However, in SHOC2 KO cells, KD of HRAS
and NRAS, but not KRAS, significantly impaired EGF-
stimulated ERK activation (Fig. 6A). Furthermore, combined
KD of HRAS and NRAS inhibited ERK activity more strongly
than NRAS/KRAS or HRAS/KRAS combinations in SHOC2
KO cells (SI Appendix, Fig. S6A). Unlike KRAS, NRAS and
HRAS are modified by palmitoylation (47) and pretreatment of
DLD-1 cells with the palmitoylation inhibitor 2-bromopalmitate
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Fig. 2. SHOC2 is required for EGF-induced S365/S259 dephosphorylation, RAF dimerization, BRAF-MEK dissociation, and efficient ERK pathway activation. (A)
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reexpression of WT but not SHOC2 mutants defective for complex formation with MRAS and PP1. Lysates from DLD-1 parental (P) and SHOC2 KO cells
transduced with lentivirures expressing flag-SHOC2 WT, mutants, or empty vector were stimulated with 25 ng/mL EGF for 5 min after serum starvation. (E)
SHOC2 is required for EGF-stimulated MEK and 14-3-3 dissociation from BRAF and BRAF dimerization with ARAF and CRAF. Serum-starved DLD-1 cells were
stimulated with EGF for the indicated times and endogenous RAF IPs immunoblotted using the Li-COR Odyssey system. (F) Li-COR quantification of CRAF,
MEK, 14-3-3 and P-S365 BRAF from BRAF IPs in E, relative to EGF-untreated parental cells. (G) BRAF S365A does not bind MEK and rescues ERK activation in
SHOC2 KO cells. DLD-1 cells, nontransduced or stably expressing T6-BRAF WT or S365A, were treated with EGF for 10 min and Streptactin pull-downs of T6-
BRAF and lysates probed as indicated.
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(2-BP) selectively reduced ERK activation at 20 min in SHOC2
KO cells (Fig. 6B). These results thus suggest that the SHOC2-
independent/CRAF-dependent sustained phase of ERK activity
is driven by palmitoylated NRAS/HRAS proteins.
To further investigate additional molecular mechanisms that
may be contributing to SHOC2-independent CRAF activation, a
panel of kinase inhibitors was tested for their ability to modulate
sustained ERK activation. In addition to ERK pathway inhibitors,
PAK (FRAX597), FAK (PF-562271), and SRC family (SU6656)
kinase inhibitors significantly impaired ERK phosphorylation at
20 min of EGF treatment in SHOC2 KO cells (Fig. 6C and SI
Appendix, Fig. S6B). Both PAK and SRC are known to phos-
phorylate the CRAF N-region at S338 and Y341, respectively,
whereas FAK has been linked to both SRC and RAC/PAK sig-
naling. Indeed, FAK inhibitors impaired PAK1 phosphorylation
and PAK, FAK, and SFK inhibitors also impaired CRAF S338
phosphorylation (Fig. 6D). Taken together, these results suggest
that N-region phosphorylation in CRAF plays an important role in
sustained ERK activation by EGF in the absence of SHOC2. A
model summarizing all our data is shown in Fig. 6E.
SHOC2 Is Selectively Required for ERK Pathway Activation under
Anchorage-Independent Conditions in KRAS Mutant Cells. We have
previously shown that SHOC2 is preferentially required for
anchorage-independent proliferation in some RASmutant cell lines
(18). We thus set out to use our isogenic DLD-1 system to elucidate
a biochemical mechanism for this observation. SHOC2 KO DLD-
1 clones had similar growth rates as parental cells in 2D but were
impaired in their ability to grow under anchorage-independent
conditions in 3D (Fig. 7 A and B). This effect was partially res-
cued by reexpression of SHOC2 WT, but not the D175N mutant
defective for MRAS/PP1 interaction (Fig. 7B), and is consistent
with a selective requirement for the RAF phosphatase function of
SHOC2 for tumorigenic properties in some RAS mutant cells.
To study a molecular mechanism for this selective SHOC2
contribution to 3D growth, lysates of parental and SHOC2 KO
DLD-1 cells growing in 2D or suspension (poly-HEMA–coated
dishes) were compared. In suspension cells, phosphorylation of
AKT and its downstream substrate site S1718 AF6 is strongly
impaired [consistent with PI3K/AKT signaling being adhesion-
dependent in many cell types (48–50)], but this is unaffected in
SHOC2 KO cells (Fig. 7 C–F). Similarly, phosphorylation of
FAK and PAK kinases, also known to be regulated by integrin-
mediated attachment to the extracellular matrix (48), was simi-
larly down-regulated in suspension in both parental and SHOC2
KO cells, which correlated with decreased phosphorylation of
known PAK sites on CRAF (S338) and MEK (S298) (Fig. 7C).
In clear contrast, basal ERK signaling, as determined by phos-
phorylation of ERK and ERK substrate sites on BRAF (T753)
and CRAF (S289/290/296), was unaffected in parental DLD-
1 cells, but significantly decreased in SHOC2 KO clones only in
suspension. A selective inhibition of ERK signaling in cells in
suspension upon SHOC2 ablation was also seen in other SHOC2
KO KRAS mutant colorectal cell lines, such as HCT116 (Fig.
7D) and SW480 (Fig. 7E) cells, but not in V600E, dimerization-
independent BRAF mutant RKO or HT29 cells (Fig. 7F). Thus,
SHOC2 is preferentially required for ERK signaling under
anchorage-independent conditions in the context of oncogenic
KRAS but not BRAF signaling.
An implication of these observations is that SHOC2-independent
mechanisms of ERK activation must predominate under 2D basal
growth conditions and that a mechanism similar to that observed in
the sustained phase of EGF stimulation involving N-region CRAF
phosphorylation by FAK/SRC or PAK kinases (Fig. 6) may also
independently operate in the context of anchorage-dependent/2D
growth. Consistent with this possibility, treatment of DLD-1 cells
growing in 2D with PAK, FAK, and SRC family inhibitors led to
decreased CRAF S338 phosphorylation in both parental and
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SHOC2 KO cells, but more potently inhibited ERK phosphoryla-
tion in the absence of SHOC2 (Fig. 7G).
Taken together, our observations suggest that SHOC2-dependent
and CRAF/N-region–dependent mechanism of RAF activation
differentially contribute to ERK activation in a context-dependent
manner: whereas redundancy makes SHOC2 dispensable for ERK
activity under anchorage-dependent 2D growth conditions, in the
absence of attachment to the extracellular matrix KRAS-mutant
cells preferentially rely on SHOC2-dependent mechanism for
ERK signaling (Discussion and SI Appendix, Fig. S8).
Discussion
This study highlights a key role for S259 RAF dephosphorylation
by the SHOC2 phosphatase complex in regulating the dissociation
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of 14-3-3 from the N-terminal RAF regulatory region and RAF
dimerization. In the absence of SHOC2, EGF-stimulated BRAF-
ARAF, BRAF-CRAF, and BRAF-KSR heterodimerization are
strongly impaired, whereas RAF interaction with RAS is actually
increased (Fig. 2B). This result shows that the RAS–RAF interaction
can be uncoupled from RAF dimerization in some contexts and is
consistent with a model where coordinate inputs from RAS and
the SHOC2 holophosphatase are required for RAF hetero-
dimerization and activation. Increased RAS–RAF interaction in
the absence of SHOC2 is incompatible with a role for SHOC2 as
a scaffold promoting RAS–RAF interaction as suggested by
some overexpression studies (29, 30). Instead, it is consistent
with decreased ERK activity in the absence of SHOC2, leading
to relief of ERK inhibitory feedbacks, both upstream of RAS and
at the level of RAF, such as CRAF S289/296/301 and BRAF
T753 that disrupt RAF–RAS interaction (51, 52). Similarly, in-
hibitory ERK feedback sites on EGFR (T699) and IRS-1 (S636/
639) are also inhibited in the absence of SHOC2 and likely
contribute to increased AKT phosphorylation upon SHOC2 and
ERK pathway inhibition (Fig. 3 A and B) (38, 39, 53).
There is controversy around the precise order of the initial steps
in the RAF activation cycle and whether S259 dephosphorylation
precedes or follows RAS-GTP binding (11). S259A mutation in
CRAF promotes association with RAS (54), which can be inter-
preted to suggest that S259 dephosphorylation may precede RAS
binding, possibly by 14-3-3 dissociation facilitating access of the
RAF RBD to RAS. However, our studies support an alternative
model (SI Appendix, Fig. S2) where RAS-GTP binding to RAF
and recruitment to the membrane is independent of, and precedes
S259 dephosphorylation by the SHOC2 complex: in a time course
of EGF stimulation, RAF binding to RAS peaks at 2.5 min and
precedes S259 dephosphorylation, which peaks at 5–10 min (Fig.
2B). Additionally, in the absence of SHOC2, under conditions
where levels of P-S259 RAF and RAF–14-3-3 complexes are high,
RAF readily interacts with RAS in response to EGF (in fact
there is increased RAS–RAF interaction; see discussion above and
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Fig. 2B). Furthermore, we have previously shown that S259 phos-
phorylation can be readily detected on the RAS-bound RAF (19).
Taken together, these observations suggest that S259-phosphorylated
RAF is able to bind to RAS and that the RAF RBD is likely to
be accessible for interaction with RAS within the closed RAF
conformation.
Our proposed model also allows for the observations that
S259A CRAF promotes RAS binding or that SHOC2 can ac-
celerate the RAS–RAF interaction (31, 54–56) when the tandem
arrangement of RBD and CRD and their cooperation in RAF
membrane localization is considered: the CRD can interact with
RAS as well as phospholipids, and helps anchor RAF at the
membrane (57–60). The CRD hydrophobic loops are likely to be
buried in the closed/inactive RAF conformation and may only be
exposed for membrane interaction in the open/active confor-
mation upon release of 14-3-3 from the regulatory domain in a
mechanism analogous to that proposed for KSR (61). According
to this possibility, CRD exposure upon S259 dephosphorylation
or experimentally in S259A RAF mutants, would increase mem-
brane avidity and stabilize RAS binding to the RBD (59, 60). We
also note that our model is consistent with the observation that a
CRAF-CAAX mutant that is constitutively localized at the
membrane, is independent of RAS but can still be further acti-
vated by EGF (62, 63) as well as by S259 dephosphorylation (SI
Appendix, Fig. S1B).
Our study suggests a role for SHOC2-mediated BRAF S365
dephosphorylation in the regulation of the BRAF–MEK in-
teraction, which inversely correlates with BRAF dimerization.
Because under resting conditions MEK interacts with BRAF
much more strongly than ARAF or CRAF, we speculate that the
unique N-terminal BRAF-specific (BRS) domain of BRAF may
mediate an additional interaction with MEK in the inactive BRAF
conformation. The BRAF BRS domain also interacts with KSR1
(64), suggesting a mechanism for competitive displacement upon
growth factor stimulated BRAF-KSR dimerization (SI Appendix,
Fig. S2). A definitive answer awaits determination of the crystal
structure of full-length BRAF in complex with 14-3-3 and MEK.
Our study has uncovered a selective contribution of the
SHOC2 phosphatase complex to ERK pathway dynamics. In
DLD-1 cells EGF stimulates ERK pathway activation in a pat-
tern consistent with a biphasic response in which SHOC2 is re-
quired for a rapid, transient phase, but not a slower, sustained
phase that instead depends on palmitoylated HRAS/NRAS and
CRAF signaling. SHOC2 complex formation is driven by MRAS-
GTP and thus its cellular location is likely to be determined pri-
marily by the membrane localization signals within the carboxyl-
terminal hypervariable region (HVR) of MRAS. The HVR of
RAS proteins directs their differential spatial segregation, with
palmitoylated HRAS and NRAS being able to signal from the
plasma membrane as well as endomembrane compartments,
whereas the polybasic-motif–containing KRAS-4B is thought to
signal exclusively from the plasma membrane (47). The MRAS
HVR contains a polybasic motif as a second membrane targeting
signal and is thus expected to closely mirror KRAS-4B in its
plasma membrane localization, while being refractory to the in-
tracellular trafficking mechanisms of palmitoylated proteins. In-
deed, overexpression of YFP/mCherry-fusion proteins in human
mammary epithelial cells supports this scenario, as in addition to
the plasma membrane, HRAS and NRAS (but not KRAS-4B or
MRAS) can be readily detected to colocalize with CRAF at the
Golgi and/or other intracellular compartments (SI Appendix,
Fig. S7).
We propose a model (Fig. 6E) where upon EGF stimulation,
the rapid phase of SHOC2-dependent ERK activation occurs at
the plasma membrane, where SHOC2 complex formation upon
MRAS activation leads to S259 dephosphorylation on proximal
A/B/C-RAF proteins recruited by H/N/K-RAS proteins. In this
phase there is redundancy among RAS and RAF isoforms for
ERK pathway activation, whereas SHOC2 appears to play an
essential, nonredundant role (Fig. 3C). The slow, sustained
phase of ERK activation may be driven by internalization of
palmitoylated RAS proteins that thereby become spatially seg-
regated from the SHOC2 complex that remains anchored at the
plasma membrane by MRAS, alongside KRAS-4B. Internaliza-
tion may result from intracellular trafficking by the constitutive
acylation cycle of palmitoylated proteins and/or receptor-
mediated endocytosis and/or other mechanisms operating in a
nonmutually exclusive manner (44, 65, 66). From these intracellular
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Fig. 7. SHOC2 is selectively required for ERK path-
way activation under anchorage-independent
conditions in KRAS mutant cells. (A) SHOC2 is dis-
pensable for anchorage-dependent/2D growth.
Incucyte growth curves of DLD-1 parental and three
independent SHOC2 KO clones stably expressing WT
and D175N SHOC2 were generated using the Incu-
Cyte Live Cell imaging system. Representative of n =
2 experiments. (B) SHOC2 KO impairs growth in 3D.
Cells in A were seeded in low attachment plates and
growth at day 5 measured by Alamar blue staining
(mean ± SD) (n = 2–4). Significance is determined
using a two tailed t test *P < 0.05, **P < 0.01, or
***P < 0.001. (C) SHOC2 is preferentially required for
ERK pathway activation in 3D in DLD-1 cells. DLD-
1 cells were grown for 24 h on regular or poly-
HEMA–coated plates and lysates immunoprobed as
indicated. (D) As in C but with HCT116 KRASG13D
cells. (E) As in C and D with SW480 KRASG12V cells. (F)
SHOC2 is dispensable for ERK phosphorylation in 2D
and 3D in the BRAF mutant (V600E) RKO and HT-
29 cell lines. (G) PAK (FRAX597), SRC (SU6656), and
FAK (PF-562271) family inhibitors inhibit basal ERK
signaling more potently in the absence of SHOC2.
DLD-1 cells growing in log phase in the presence of
10% FBS were incubated with 10-μM inhibitors for
1 h and lysates immunoblotted as indicated.
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compartments, H/N-RAS proteins signal primarily through CRAF,
which is now uncoupled from regulation by the SHOC2 complex
but dependent on N-region phosphorylation by kinases such as
PAK, SRC, and FAK (directly or indirectly).
A biphasic HRAS activation by EGF with a slow sustained
phase at the Golgi dependent on the acylation cycle (44, 65, 67), as
well as differential CRAF activation by HRAS (but not KRAS)
dependent on endocytosis (45), are both consistent with this
model. A similar biphasic ERK response upon G protein-coupled
receptor internalization has been linked to phosphorylation of
different ERK substrates from spatially distinct signaling platforms
(1, 68) and it is likely that SHOC2-dependent and -independent
phases of ERK activation are also associated with phosphorylation
of ERK substrates at distinct spatial compartments. We also note
that similar biphasic kinetics linked to compartment-specific RAS-
ERK signaling have been observed during the process of thymo-
cyte selection (66, 69) and future studies should address the role of
the SHOC2 complex in immune tolerance.
The contribution of CRAF S259 dephosphorylation and/or
dimerization to the slow ERK activation phase remains unclear.
We were unable to detect significant S259 dephosphorylation or
RAF heterodimerization in the absence of SHOC2, but low levels
below the sensitivity of our experimental conditions cannot be
ruled out. On the other hand, we note that experimental con-
straints when analyzing endogenous proteins have not allowed us
to measure homodimerization, and S259-independent CRAF
homodimerization during the slow, sustained phase remains a
distinct possibility. Reports of N-region CRAF phosphorylation
promoting relief from autoinhibition and dimerization (70, 71)
and of high levels of S338 phosphorylation activating CRAF in the
presence of high levels of inhibitory phosphorylation at S43 and
S259 (72) support this scenario. It is also worth noting that both
SFK and PAK activators, such as RAC and CDC42, are palmi-
toylated and expected to travel with H/N-RAS during both en-
docytosis and acylation cycle scenarios of intracellular trafficking,
which would thus facilitate N-region phosphorylation of the H/N-
RAS bound CRAF at these compartments.
The biochemical mechanisms of SHOC2-independent, CRAF
N-region–dependent ERK activation observed in the sustained
phase of EGF stimulation in DLD-1 cells appear to operate as well
in the context of anchorage-dependent proliferation in 2D (SI Ap-
pendix, Fig. S8). Integrin signaling regulates both FAK-SRC and
PAK activation and cooperates with RTKs to regulate sustained
ERK activation in multiple contexts (73–79). Thus, integrins are
well poised to mediate, at least in part, SHOC2-independent ERK
activation from sites of attachment to the extracellular matrix.
Redundant SHOC2-dependent and SHOC2-independent/
CRAF-dependent mechanisms of ERK activation under basal
2D conditions are likely to account for the observation that both
SHOC2 and CRAF ablation alone are well tolerated, whereas
combined inhibition potently inhibits growth (Fig. 5E), as com-
plete inhibition of the ERK response is incompatible with pro-
liferation (8, 41, 42). In clear contrast however, in the absence of
adhesion to the extracellular matrix, a key contribution of
SHOC2 to ERK activity in KRAS mutant cells is uncovered in 3D
(Fig. 7). Basal PI3K/AKT and FAK/PAK activation is strongly
impaired in the absence of matrix-dependent attachment, which is
likely to enhance the dependency on SHOC2-dependent ERK
signaling for anchorage-independent growth in RAS mutant cells
(18). Taken together, our results thus provide a molecular mech-
anism for a selective RAS oncogene addiction to SHOC2 that has
also been observed in other studies (80, 81) (https://depmap.org)
and presents a therapeutic opportunity.
Current ERK pathway inhibitors have failed in the clinic
against RAS-driven cancers primarily because toxicity precludes
a therapeutic index. Our study suggests the SHOC2 phosphatase
complex functions as a regulatory node for only a subset of the
ERK signaling response. Thus, in contrast to targeting RAF/
MEK/ERK core pathway components that inhibit global ERK
signaling, targeting the SHOC2 complex may provide a mecha-
nism for selective ERK pathway inhibition that may provide
better therapeutic margins against RAS-driven tumors. PP1
holophophosphatases remain underexplored targets of pharma-
cological inhibition (82–84) and future efforts should drive de-
velopment of inhibitors of the SHOC2 holophosphatase.
In summary, this study highlights a selective contribution of
the SHOC2 phosphatase complex to RAF regulation and ERK
pathway spatiotemporal dynamics that is differentially engaged
by KRAS oncogenic signaling and that may allow for context and
compartment-specific inhibition of ERK signaling.
Materials and Methods
Cell Proliferation in Anchorage-Dependent and Independent Assays. Growth
curves in 24-well plates were generated using the IncuCyte system (Essen
BioScience). Pictures were taken every 2 h, with each data point a composite
of four different images from the same well. Growth medium was replaced
every 2 d.
Anchorage-independent growth (or growth in 3D)was assessed by seeding
1,000 cells in 384-well ultralow attachment plates (Greiner). After 5 d, Alamar
blue was added to cells and fluorescence measured using a plate reader.
Colony assays were performed 2 d after the siRNA transfection by seeding
2,000 cells in 24-well plates or 30,000 cells in 6-well plates. Cells were grown
for 10 d replacing media every 2 d, stained with 0.5% Crystal violet, and
photographed using a digital scanner.
Cell Lysis and IP Assays. Cells were lysed in PBS with 1% Triton-X-100, protease
inhibitor mixture (Roche), phosphatase inhibitor mixture, and either 1 mM
EDTA or 5 mM MgCl2. Tagged proteins were immunoprecipitated/pulled
down from cleared lysates using either FLAG (M2) agarose (Millipore Sigma),
glutathione Sepharose, or Streptactin beads (GE Healthcare). Endogenous
proteins were immunoprecipitated using antibodies (SI Appendix, Supple-
mentary Materials and Methods) and protein A/G beads (GE Healthcare).
After 2-h rotating incubation at 4 °C, beads were extensively washed with
PBS-E or PBS-M lysis buffer, drained, and resuspended in NuPAGE LDS
sample buffer (Life Technologies). Samples were analyzed by Western blot
with HRP (GE Healthcare) and DyLight (Thermo Scientific) conjugated sec-
ondary antibodies. Membranes were visualized using an Odyssey scanner
(Li-COR) or Image Quant system (GE Healthcare).
Statistical Analysis. Data are presented as mean ± SD. Significance was de-
termined with GraphPad Prism 7 software using the Student’s t test, where
*P < 0.05, **P < 0.01, or ***P < 0.001.
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